Zacks Research Brokers Raise Earnings Estimates for BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Stock analysts at Zacks Research boosted their Q1 2025 earnings per share estimates for shares of BioMarin Pharmaceutical in a research note issued to investors on Wednesday, January 8th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $0.61 for the quarter, up from their prior forecast of $0.60. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.49 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s FY2025 earnings at $2.68 EPS, Q2 2026 earnings at $0.84 EPS and Q3 2026 earnings at $0.89 EPS.

Several other analysts have also issued reports on BMRN. William Blair lowered shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 30th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $80.00 target price on shares of BioMarin Pharmaceutical in a report on Wednesday, October 30th. Bank of America lowered their price target on BioMarin Pharmaceutical from $130.00 to $115.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. Canaccord Genuity Group reduced their price objective on BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating on the stock in a research note on Wednesday, October 30th. Finally, Barclays lowered their target price on BioMarin Pharmaceutical from $110.00 to $86.00 and set an “overweight” rating for the company in a research note on Friday, October 4th. Seven analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.20.

BioMarin Pharmaceutical Price Performance

BMRN stock opened at $68.38 on Friday. The company’s 50-day moving average price is $65.81 and its two-hundred day moving average price is $75.23. The firm has a market cap of $13.03 billion, a P/E ratio of 40.95, a P/E/G ratio of 0.65 and a beta of 0.29. The company has a quick ratio of 2.62, a current ratio of 4.27 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical has a 12 month low of $61.15 and a 12 month high of $98.23.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The company had revenue of $746.00 million during the quarter, compared to the consensus estimate of $703.37 million. During the same quarter in the previous year, the business posted $0.26 EPS. The firm’s revenue for the quarter was up 28.4% on a year-over-year basis.

Insider Activity at BioMarin Pharmaceutical

In other news, EVP Charles Greg Guyer sold 5,278 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total value of $350,300.86. Following the completion of the transaction, the executive vice president now directly owns 68,909 shares of the company’s stock, valued at approximately $4,573,490.33. This trade represents a 7.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.85% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Large investors have recently added to or reduced their stakes in the business. Tokio Marine Asset Management Co. Ltd. boosted its holdings in shares of BioMarin Pharmaceutical by 0.8% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 21,105 shares of the biotechnology company’s stock worth $1,483,000 after buying an additional 173 shares in the last quarter. Advisors Asset Management Inc. lifted its position in shares of BioMarin Pharmaceutical by 1.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 11,451 shares of the biotechnology company’s stock valued at $805,000 after acquiring an additional 180 shares during the period. TD Private Client Wealth LLC boosted its stake in BioMarin Pharmaceutical by 57.4% during the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 186 shares in the last quarter. First Hawaiian Bank grew its holdings in BioMarin Pharmaceutical by 1.4% in the fourth quarter. First Hawaiian Bank now owns 14,700 shares of the biotechnology company’s stock worth $966,000 after purchasing an additional 200 shares during the period. Finally, Voisard Asset Management Group Inc. increased its stake in BioMarin Pharmaceutical by 17.8% in the third quarter. Voisard Asset Management Group Inc. now owns 1,355 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 205 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.